Adagrasib for previously treated KRAS G12C mutated advanced non-small-cell lung cancer
Adagrasib is currently in clinical development for the treatment of KRAS G12C mutated advanced non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Only a small subset of NSCLC patients carry the KRAS G12C mutation. When NSCLC spreads to other parts of the body, it is called advanced NSCLC. Treatment options […]